Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 59 results for women%27s health

  1. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

  2. Long-term safety of ovarian stimulation and ovulation induction for women:- Is there an association between ovulation induction or ovarian stimulation and adverse long-term (over 20 years) effects in women in the UK?

    induction for women:- Is there an association between ovulation induction or ovarian stimulation and adverse long-term (over 20 years)...

  3. Blood transfusion (NG24)

    This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.

  4. Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

    This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.

  5. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  6. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  7. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (TA810)

    Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.

  8. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

  9. Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)

    NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .

  10. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

  11. TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)

    NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .

  12. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

  13. The Epidrum for aiding access to the epidural space (MIB23)

    NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space

  14. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

  15. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.